Wuxi AppTec Corporate Ventures has participated in a round that will support development of NuProbe's molecular blood test.

US-based medical diagnostics technology developer NuProbe has received $11m in a series A round featuring WuXi AppTec Corporate Ventures, healthcare group WuXi AppTec’s corporate venturing unit.

Sequoia Capital China, an affiliate firm of venture capital firm Sequoia Capital, co-led the round with hedge fund manager Serica Partners.

NuProbe has developed a molecular blood test that helps medical researchers promptly detect rare genetic variants that could be indicative of diseases such as cancer. The test works by identifying malignant instances of…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?